254 related articles for article (PubMed ID: 11157426)
1. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials.
Barbui C; Hotopf M
Br J Psychiatry; 2001 Feb; 178():129-44. PubMed ID: 11157426
[TBL] [Abstract][Full Text] [Related]
2. Amitriptyline for depression.
Guaiana G; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2007 Jul; (3):CD004186. PubMed ID: 17636748
[TBL] [Abstract][Full Text] [Related]
3. Amitriptyline versus other types of pharmacotherapy for depression.
Guaiana G; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2003; (2):CD004186. PubMed ID: 12804503
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity.
Hotopf M; Hardy R; Lewis G
Br J Psychiatry; 1997 Feb; 170():120-7. PubMed ID: 9093499
[TBL] [Abstract][Full Text] [Related]
5. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
Cochrane Database Syst Rev; 2007 Jul; (3):CD002791. PubMed ID: 17636706
[TBL] [Abstract][Full Text] [Related]
6. Fluoxetine versus other types of pharmacotherapy for depression.
Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
[TBL] [Abstract][Full Text] [Related]
7. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.
Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
Cochrane Database Syst Rev; 2000; (4):CD002791. PubMed ID: 11034764
[TBL] [Abstract][Full Text] [Related]
8. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
Anderson IM
J Affect Disord; 2000 Apr; 58(1):19-36. PubMed ID: 10760555
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine versus other types of pharmacotherapy for depression.
Cipriani A; Brambilla P; Furukawa T; Geddes J; Gregis M; Hotopf M; Malvini L; Barbui C
Cochrane Database Syst Rev; 2005 Oct; (4):CD004185. PubMed ID: 16235353
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the efficacy of traditional antidepressive agents and the new generation of antidepressives in the treatment of depressive disorders].
Cvjetković-Bosnjak M; Knezević A; Soldatović-Stajić B
Med Pregl; 1999; 52(3-5):108-11. PubMed ID: 10518394
[TBL] [Abstract][Full Text] [Related]
11. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.
Anderson IM
Depress Anxiety; 1998; 7 Suppl 1():11-7. PubMed ID: 9597346
[TBL] [Abstract][Full Text] [Related]
12. Fluvoxamine versus other anti-depressive agents for depression.
Omori IM; Watanabe N; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA
Cochrane Database Syst Rev; 2010 Mar; (3):CD006114. PubMed ID: 20238342
[TBL] [Abstract][Full Text] [Related]
13. Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis.
MacGillivray S; Arroll B; Hatcher S; Ogston S; Reid I; Sullivan F; Williams B; Crombie I
BMJ; 2003 May; 326(7397):1014. PubMed ID: 12742924
[TBL] [Abstract][Full Text] [Related]
15. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
Berndt ER; Bhattacharjya A; Mishol DN; Arcelus A; Lasky T
J Ment Health Policy Econ; 2002 Mar; 5(1):3-19. PubMed ID: 12529566
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
[TBL] [Abstract][Full Text] [Related]
17. Are SSRIs a cost-effective alternative to tricyclics?
Hotopf M; Lewis G; Normand C
Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis.
Arroll B; Macgillivray S; Ogston S; Reid I; Sullivan F; Williams B; Crombie I
Ann Fam Med; 2005; 3(5):449-56. PubMed ID: 16189062
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
20. WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression.
Geddes JR; Freemantle N; Mason J; Eccles MP; Boynton J
Cochrane Database Syst Rev; 2007 Jul; 2006(3):CD001851. PubMed ID: 17636689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
